Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (701-710 of 934) with videos related to

Pageof 94
Sort By:
Journal of the American Heart Association|October 26, 2017
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) TrialClaes Held, Harvey D White, Ralph A H Stewart, et al.
Circulation|January 21, 1997
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trialC P Cannon, C H McCabe, C M Gibson, et al.
American Heart Journal|December 9, 2008
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromesChristopher P Cannon, Robert P Giugliano, Michael A Blazing, et al.
Journal of the American College of Cardiology|January 10, 2009
Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) RegistryDeborah B Diercks, Michael C Kontos, Anita Y Chen, et al.
Circulation. Cardiovascular Interventions|April 8, 2020
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI TrialNatalia C Berry, Laura Mauri, Philippe Gabriel Steg, et al.
The New England Journal of Medicine|March 11, 2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevationMarc S Sabatine, Christopher P Cannon, C Michael Gibson, et al.
Circulation|November 18, 2005
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 TrialMarc S Sabatine, David A Morrow, Gilles Montalescot, et al.
European Heart Journal|April 15, 2014
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trialDaniel Lindholm, Christoph Varenhorst, Christopher P Cannon, et al.
American Heart Journal|October 6, 2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)Christopher P Cannon, Darren K McGuire, Richard Pratley, et al.
The New England Journal of Medicine|June 23, 2001
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofibanC P Cannon, W S Weintraub, L A Demopoulos, et al.
Pageof 94

Showing results (701-710 of 934) with videos related to

Sort By:
Pageof 94
Journal of the American Heart Association|October 26, 2017
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) TrialClaes Held, Harvey D White, Ralph A H Stewart, et al.
Circulation|January 21, 1997
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trialC P Cannon, C H McCabe, C M Gibson, et al.
American Heart Journal|December 9, 2008
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromesChristopher P Cannon, Robert P Giugliano, Michael A Blazing, et al.
Journal of the American College of Cardiology|January 10, 2009
Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) RegistryDeborah B Diercks, Michael C Kontos, Anita Y Chen, et al.
Circulation. Cardiovascular Interventions|April 8, 2020
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI TrialNatalia C Berry, Laura Mauri, Philippe Gabriel Steg, et al.
The New England Journal of Medicine|March 11, 2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevationMarc S Sabatine, Christopher P Cannon, C Michael Gibson, et al.
Circulation|November 18, 2005
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 TrialMarc S Sabatine, David A Morrow, Gilles Montalescot, et al.
European Heart Journal|April 15, 2014
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trialDaniel Lindholm, Christoph Varenhorst, Christopher P Cannon, et al.
American Heart Journal|October 6, 2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)Christopher P Cannon, Darren K McGuire, Richard Pratley, et al.
The New England Journal of Medicine|June 23, 2001
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofibanC P Cannon, W S Weintraub, L A Demopoulos, et al.
Pageof 94